A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

This study has been completed.
Information provided by:
UCB Pharma
ClinicalTrials.gov Identifier:
First received: March 3, 2005
Last updated: December 5, 2013
Last verified: February 2010

A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.

Condition Intervention Phase
Epilepsy, Partial
Drug: Levetiracetam
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mg/kg/Day, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4 - 16 Years Old, Inclusive, With Refractory Partial Onset Seizures

Resource links provided by NLM:

Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • Characterize potential cognitive and neuropsychological effects of levetiracetam as adjunctive treatment in children 4-16 years old with refractory partial onset seizures compared to placebo attention/memory scale (Leiter-R) a

Secondary Outcome Measures:
  • Scores on memory/learning battery (WRAML-2), behavioral scale (CBCL), and quality of life scale (CHQ) after 12 weeks of double blind treatment

Estimated Enrollment: 87
Study Start Date: September 2004
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   4 Years to 16 Years
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Pediatric subjects (4 - 16 years old) diagnosed with refractory partial onset seizures for a minimum of six months prior to Visit 1 experiencing at least two partial onset seizures during the four weeks prior to Visit 1 will be enrolled.
  • Subjects should be on a stable regimen of one or a maximum of two other AEDs for at least 2 weeks prior to Visit 1.
  • Subject must have an Intelligence Quotient (IQ) as assessed during Visit 1 of at least 70.
  • Subject and parent/guardian should be fluent in English.

Exclusion Criteria:

  • Subject must not have had previous treatment with levetiracetam unless, in the opinion of the investigator, the subject's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of levetiracetam was confounded by concomitant medication.
  • Subject is receiving benzodiazepines on a routine or chronic basic and is unable to discontinue use four weeks prior to Visit 1.
  • Subject has seizures too close together to accurately count.
  • Subject has a current psychiatric disorder other than mild to moderate attention deficit, behavior, or learning disorders.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00105040

  Hide Study Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
La Jolla, California, United States
Los Angeles, California, United States
United States, Colorado
Denver, Colorado, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Bradenton, Florida, United States
Gainesville, Florida, United States
Loxahatchee, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
Tallahassee, Florida, United States
Tampa, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Augusta, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, New Jersey
Voorhees, New Jersey, United States
United States, New York
Buffalo, New York, United States
New York, New York, United States
Rochester, New York, United States
United States, North Carolina
Winston-Salem, North Carolina, United States
United States, Ohio
Cleveland, Ohio, United States
United States, Pennsylvania
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, South Carolina
Charleston, South Carolina, United States
United States, Tennessee
Germantown, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Fort Worth, Texas, United States
Galveston, Texas, United States
Houston, Texas, United States
United States, Virginia
Norfolk, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Seattle, Washington, United States
United States, West Virginia
Morgantown, West Virginia, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Canada, Ontario
Scarborough, Ontario, Canada
Thornhill, Ontario, Canada
Toronto, Ontario, Canada
South Africa
Bloemfontein, South Africa
Cape Town, South Africa
Capitol Park, South Africa
Johannesburg, South Africa
Sponsors and Collaborators
UCB Pharma
Study Director: UCB Clinical Trial Call Center UCB Pharma
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00105040     History of Changes
Other Study ID Numbers: N01103
Study First Received: March 3, 2005
Last Updated: December 5, 2013
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by UCB Pharma:
Partial onset seizures

Additional relevant MeSH terms:
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Central Nervous System Agents
Neuroprotective Agents
Nootropic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 21, 2014